라파엘 홀딩스(RFL)는 NYSE에 상장된 Real Estate · Real Estate Services 기업입니다. 현재가 $1.99 (+1.02%), 시가총액 $0.07B, 52주 범위 $1.16 ~ $2.85.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic inter
라파엘 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
라파엘 홀딩스의 현재 주가는 $1.99 (+1.02%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
라파엘 홀딩스의 시가총액은 약 $0.07B입니다.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, H